Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same authorSame journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026

Same author

Is supplemental vitamin D useful in the clinically isolated syndrome (CIS) typical of multiple sclerosis?

Expert opinion on pharmacotherapy·2026

Same author

Is seltorexant, an orexin-2 receptor antagonist, showing promise in insomnia?

Expert opinion on investigational drugs·2026

Same author

Does varenicline promote abstinence in youths who vape?

Expert opinion on pharmacotherapy·2025

Same author

Reply to: reframing guselkumab's benefit in ulcerative colitis: insights from QUASAR and emerging evidence.

Expert opinion on biological therapy·2025

Same author

With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?

Expert opinion on biological therapy·2025

Search research articles

Related Experiment Video

Updated: Jul 30, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Efalizumab for psoriasis?

Sheila A Doggrell¹

¹Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s.doggrell@xtra.co.nz

Expert Opinion on Investigational Drugs

|May 25, 2004

Summary

Efalizumab significantly improved plaque psoriasis symptoms and quality of life in patients. Further trials are needed to compare efalizumab with other psoriasis treatments.

Area of Science:

Immunodermatology
Pharmacology

Background:

Psoriasis is a chronic inflammatory skin condition.
Efalizumab is a monoclonal antibody targeting T-lymphocyte migration.

Purpose of the Study:

To evaluate the efficacy of efalizumab in treating plaque psoriasis.
To assess the impact of efalizumab on patient quality of life.

Main Methods:

A clinical trial comparing efalizumab to placebo in plaque psoriasis patients.
Assessment of treatment response at week 12, including >75% improvement criteria.

Main Results:

51-52% of efalizumab-treated patients showed improvement versus 17% for placebo at 12 weeks.
22-28% of efalizumab patients achieved >75% improvement, compared to 5% for placebo.

More Related Videos

Measuring Psoriasis Severity at Home

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Related Experiment Videos

Last Updated: Jul 30, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Measuring Psoriasis Severity at Home

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Efalizumab treatment positively impacted quality-of-life outcomes.

Conclusions:

Efalizumab demonstrates significant efficacy in treating plaque psoriasis.
Comparative trials are necessary to determine optimal treatment strategies among emerging psoriasis therapies.